Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm first-line camrelizumab + pyrotinib + nab-paclitaxel + tegafur study in HER2-positive gastric cancer
ChiCTR2100051618Phase 2Recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, pyrotinib, paclitaxel and tegafur in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Objective response rate. Started Oct 2021; status: recruiting.
02
Drugs
camrelizumabpyrotinibpaclitaxeltegafur
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2100051618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051618.